Key result
Intravenous injection of DOX-Cur NPs efficiently inhibited growth of subcutaneous 4T1 breast carcinoma in vivo (p < 0.01) and prolonged survival with less cardiac damage than free DOX.
Why the study?
Does co-delivery of doxorubicin and curcumin via nanoparticles improve anti-tumor efficacy and reduce cardiotoxicity in a 4T1 breast carcinoma mouse model?
Does co-delivery of doxorubicin and curcumin via nanoparticles improve anti-tumor efficacy and reduce cardiotoxicity in a 4T1 breast carcinoma mouse model?
p-value: p=<0.01
Co-delivery of doxorubicin and curcumin via nanoparticles enhances anti-tumor efficacy and reduces doxorubicin-induced cardiotoxicity in a breast cancer mouse model.
Use of single chemotherapy agents has shown some limitations in anti-tumor treatment, such as development of drug resistance, severe adverse reactions and limited regime for therapeutic use. Combination of two or more therapeutic drugs is a feasible strategy to overcome these limitations. This paper reports study of co-delivery by core-shell nanoparticles (NPs) with hydrophobic PLLA core loaded with curcumin (Cur) and hydrophilic heparin shell adsorbing Doxorubicin (DOX). Characterizations of Cur-PEA NPs, Cur-PEA/heparin NPs and DOX adsorbing into Cur-PEA/heparin NPs (DOX-Cur NPs) were also investigated by transmission electron microscope (TEM) and Malvern Zetasizer. Studies on cellular uptake of DOX-Cur NPs demonstrated that both drugs were effectively taken up by 4T1 tumor cells. Furthermore, DOX-Cur NPs suppressed 4T1 tumor cells growth more efficiently than either DOX or Cur alone at the same concentrations, as measured by flow cytometry (FCM). We found out that intravenous injection of DOX-Cur NPs efficiently inhibited growth of subcutaneous 4T1 breast carcinoma in vivo (p < 0.01) and prolonged survival of the treated 4T1 breast carcinoma mice. Moreover, the pathological damage to the cardiac tissue in mice treated with DOX-Cur NPs was significantly less severe than that of mice treated with free DOX. This study suggested that DOX-Cur NPs may have promising applications in breast carcinoma therapy.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2013) studied 4T1 breast carcinoma. DOX-Cur NPs (Doxorubicin and Curcumin core-shell nanoparticles) vs. DOX alone, Cur alone, or free DOX was evaluated on Tumor growth inhibition (p=<0.01). Intravenous injection of DOX-Cur NPs efficiently inhibited growth of subcutaneous 4T1 breast carcinoma in vivo (p < 0.01) and prolonged survival with less cardiac damage than free DOX.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: